Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).

Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, Anastasakis A, Weintraub R, Biagini E, Ragni L, Prendiville T, Duignan S, McLeod K, Ilina M, Fernández A, Bökenkamp R, Baban A, Kubuš P, Daubeney PEF, Sarquella-Brugada G, Cesar S, Marrone C, Bhole V, Medrano C, Uzun O, Brown E, Gran F, Castro FJ, Stuart G, Vignati G, Barriales-Villa R, Guereta LG, Adwani S, Linter K, Bharucha T, Garcia-Pavia P, Rasmussen TB, Calcagnino MM, Jones CB, De Wilde H, Toru-Kubo J, Felice T, Mogensen J, Mathur S, Reinhardt Z, O'Mahony C, Elliott PM, Omar RZ, Kaski JP.

JAMA Cardiol. 2019 Aug 14. doi: 10.1001/jamacardio.2019.2861. [Epub ahead of print]

PMID:
31411652
2.

A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators.

Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.

PMID:
24126876
3.

International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).

O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, Cecchi F, Olivotto I, Kitaoka H, Gotsman I, Carr-White G, Mogensen J, Antoniades L, Mohiddin SA, Maurer MS, Tang HC, Geske JB, Siontis KC, Mahmoud KD, Vermeer A, Wilde A, Favalli V, Guttmann OP, Gallego-Delgado M, Dominguez F, Tanini I, Kubo T, Keren A, Bueser T, Waters S, Issa IF, Malcolmson J, Burns T, Sekhri N, Hoeger CW, Omar RZ, Elliott PM.

Circulation. 2018 Mar 6;137(10):1015-1023. doi: 10.1161/CIRCULATIONAHA.117.030437. Epub 2017 Nov 30.

PMID:
29191938
4.

Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM, Kaski JP.

Eur J Prev Cardiol. 2017 Jul;24(11):1220-1230. doi: 10.1177/2047487317702519. Epub 2017 May 9. Review.

PMID:
28482693
5.

Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.

6.

Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.

Ruiz-Salas A, García-Pinilla JM, Cabrera-Bueno F, Fernández-Pastor J, Peña-Hernández J, Medina-Palomo C, Barrera-Cordero A, De Teresa E, Alzueta J.

Europace. 2016 May;18(5):773-7. doi: 10.1093/europace/euv079. Epub 2015 Apr 7.

PMID:
25855675
7.
8.

Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.

Vieira AP, Adragão PP, Santos KR, Morgado FB, Cavaco DM, Rossi R, Abecasis M, Neves JP, Bonhosrst D, Gomes JL, Gomes RS.

Rev Port Cardiol. 2005 Mar;24(3):407-15. English, Portuguese.

PMID:
15929624
9.

The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.

Freitas P, Ferreira AM, Arteaga-Fernández E, de Oliveira Antunes M, Mesquita J, Abecasis J, Marques H, Saraiva C, Matos DN, Rodrigues R, Cardim N, Mady C, Rochitte CE.

J Cardiovasc Magn Reson. 2019 Aug 15;21(1):50. doi: 10.1186/s12968-019-0561-4.

10.

Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.

Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Hansen PR, Seggewiss H, Horstkotte D, Adlova R, Michels M, Bundgaard H, Ten Berg JM, Veselka J.

Europace. 2018 Sep 1;20(FI2):f198-f203. doi: 10.1093/europace/eux251.

PMID:
29016960
11.

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ.

JAMA Cardiol. 2019 Jul 1;4(7):644-657. doi: 10.1001/jamacardio.2019.1391.

PMID:
31116360
12.

Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy.

O'Mahony C, Jichi F, Monserrat L, Ortiz-Genga M, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators*.

Circ Arrhythm Electrophysiol. 2016 Jun;9(6). pii: e003818. doi: 10.1161/CIRCEP.115.003818.

PMID:
27217341
13.

Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, Willems R, Michels M.

Circ Arrhythm Electrophysiol. 2015 Aug;8(4):829-35. doi: 10.1161/CIRCEP.114.002553. Epub 2015 Apr 28.

PMID:
25922410
14.

[Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].

Li WX, Liu LW, Wang J, Zuo L, Yang F, Kang N, Lei CH.

Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Dec 24;45(12):1033-1038. doi: 10.3760/cma.j.issn.0253-3758.2017.12.006. Chinese.

PMID:
29325362
15.

A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.

Norrish G, Ding T, Field E, McLeod K, Ilina M, Stuart G, Bhole V, Uzun O, Brown E, Daubeney PEF, Lota A, Linter K, Mathur S, Bharucha T, Kok KL, Adwani S, Jones CB, Reinhardt Z, Omar RZ, Kaski JP.

Europace. 2019 Oct 1;21(10):1559-1565. doi: 10.1093/europace/euz118.

PMID:
31155643
16.

Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.

Avanesov M, Münch J, Weinrich J, Well L, Säring D, Stehning C, Tahir E, Bohnen S, Radunski UK, Muellerleile K, Adam G, Patten M, Lund G.

Eur Radiol. 2017 Dec;27(12):5136-5145. doi: 10.1007/s00330-017-4869-x. Epub 2017 Jun 14.

PMID:
28616729
17.

Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.

JAMA. 2007 Jul 25;298(4):405-12. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
17652294
18.

[Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients].

Zhu SH, Li Y, Huang W, Jiang H, Li SN, Chen L, Huang S, Yu HS, Xu B.

Zhonghua Xin Xue Guan Bing Za Zhi. 2017 May 24;45(5):404-408. doi: 10.3760/cma.j.issn.0253-3758.2017.05.008. Chinese.

PMID:
28511325
19.

Aborted sudden cardiac death (SCD) in a patient with hypertrophic cardiomyopathy (HCM) with low-risk factors for SCD.

Kaushik S, Subramanian SR, Rafii S, Castillo R.

BMJ Case Rep. 2013 Jan 25;2013. pii: bcr2012006459. doi: 10.1136/bcr-2012-006459.

20.

Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy.

Magri D, Agostoni P, Sinagra G, Re F, Correale M, Limongelli G, Zachara E, Mastromarino V, Santolamazza C, Casenghi M, Pacileo G, Valente F, Morosin M, Musumeci B, Pagannone E, Maruotti A, Uguccioni M, Volpe M, Autore C.

Int J Cardiol. 2018 Nov 15;271:125-131. doi: 10.1016/j.ijcard.2018.04.019. Epub 2018 Aug 4.

PMID:
30087038

Supplemental Content

Support Center